Fuller H B vs Stepan
FUL and SCL side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FUL and SCL compare
Fuller H B is the larger company, worth 1.8 times as much as Stepan ($2.7B against $1.5B).
On earnings, Fuller H B is cheaper: it trades at 14.1× trailing earnings, against 347× for Stepan.
Stepan grew revenue faster over the last twelve months (10.0% versus 1.5% for Fuller H B).
Fuller H B keeps more of each dollar of sales as profit, with a net margin of 5.6% compared with 0.17% at Stepan.
Both pay dividends: Fuller H B yields 1.9% and Stepan 2.4%.
Fuller H B scores higher on the StockData Score (18 against 7 for Stepan), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FUL | SCL |
|---|---|---|
| Size and price | ||
| Market cap | $2.7B | $1.5B |
| Share price | $50.65 | $65.94 |
| Change, 1 year | −12.3% | 50.0% |
| Change, 5 years | −33.8% | −45.5% |
| Beta (5Y) | 0.96 | 0.87 |
| Employees | 7,100 | – |
| StockData Score | ||
| Total score | 18 (better) | 7 |
| Valuation score | 6 (better) | 1 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 14.1× (better) | 347× |
| P/S | 0.8× | 0.6× (better) |
| P/B | 1.3× | 1.2× (better) |
| EV/EBITDA | 8.0× (better) | 13.4× |
| P/FCF | 27.3× (better) | 329× |
| FCF yield | 3.7% (better) | 0.30% |
| Fair value | $103.58 | $56.29 |
| Margin of safety | 51.1% (better) | −17.1% |
| Growth | ||
| Revenue growth (TTM) | 1.5% | 10.0% (better) |
| Revenue growth, 5Y average | 4.5% | 4.5% (better) |
| Net income growth (TTM) | 72.2% (better) | −90.4% |
| EPS growth (TTM) | 71.8% (better) | −90.4% |
| EPS growth, 5Y average | 3.1% (better) | −17.8% |
| Profitability | ||
| Gross margin | 32.3% (better) | 12.0% |
| Operating margin | – | 0.95% |
| Net margin | 5.6% (better) | 0.17% |
| FCF margin | 2.8% (better) | 0.18% |
| Return on equity | 9.6% (better) | 0.35% |
| Return on invested capital | – | 1.4% |
| Financial health | ||
| Debt / equity | 0.95 | 0.52 (better) |
| Net debt / EBITDA | 3.35 (better) | 3.53 |
| Current ratio | 1.82 (better) | 1.32 |
| Altman Z-score | 1.86 | 2.72 (better) |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | 2.4% (better) |
| Payout ratio | 26.2% | 830% |
| Years of dividend growth | 16 | 16 |
| Dividend growth, 5Y average | 7.4% (better) | 6.5% |
| Buyback yield | 1.8% | – |
| Shareholder yield | 3.7% (better) | 2.4% |
| Ownership | ||
| Held by institutions | 104% | 87.6% |
| Held by insiders | 0.65% | 4.8% |
| Insider net buying, 12 months | $914K | – |
| Short interest, % of float | 4.1% | 3.1% |
Go deeper
- FUL stock overview
- FUL income statement
- FUL valuation and score
- SCL stock overview
- SCL income statement
- SCL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.